Last updated: September 8, 2026
Gadoteridol is a mature macrocyclic gadolinium-based contrast agent marketed in the United States as ProHance by Bracco Diagnostics. Its FDA approval dates to 1992, and its core composition and product patents have expired. The product remains commercially relevant because of demand for contrast-enhanced MRI and physician preference for macrocyclic agents, but its growth is constrained by generic competition, contracting pressure, and competition from gadobutrol and gadoterate meglumine.
Bracco does not publicly disclose standalone ProHance revenue. The financial trajectory is therefore best assessed through market drivers, product positioning, pricing pressure, regulatory status, and the performance of the broader MRI contrast media market.
What is gadoteridol and how is it used?
Gadoteridol is a macrocyclic, nonionic gadolinium-based contrast agent used for intravenous MRI enhancement of the central nervous system, including the brain, spine, and associated tissues. The U.S. product is supplied as ProHance injection in concentrations of 279.3 mg/mL, equivalent to 0.5 mmol/mL of gadoteridol [1].
What are the principal clinical indications?
The FDA-approved indications include:
- MRI of the brain in adults and pediatric patients
- MRI of the spine in adults and pediatric patients
- MRI of the head and neck in adults and pediatric patients
The recommended dose is generally 0.1 mmol/kg, or 0.2 mL/kg, although the label permits repeat dosing in selected circumstances [1].
Gadoteridol is administered intravenously and is cleared primarily through the kidneys. The label includes a boxed warning concerning nephrogenic systemic fibrosis in patients with severe renal impairment and warnings regarding gadolinium retention [1].
What is the FDA regulatory status of ProHance?
ProHance was approved by the FDA in 1992. It is a prescription diagnostic product, not a therapeutic drug, and it does not receive biologic exclusivity or biosimilar protection.
| Regulatory item |
Gadoteridol / ProHance status |
| Active ingredient |
Gadoteridol |
| Dosage form |
Intravenous injection |
| FDA product |
ProHance |
| Original U.S. approval |
1992 |
| Marketing company |
Bracco Diagnostics Inc. |
| Therapeutic category |
MRI contrast agent |
| FDA pathway |
New drug application |
| Biologic product |
No |
| Biosimilar pathway |
Not applicable |
| Primary risks |
Gadolinium retention, hypersensitivity, renal impairment-related NSF |
| U.S. approval status |
Approved and marketed |
The product’s mature regulatory history limits the scope for new exclusivity. Commercial performance depends primarily on formulary access, hospital purchasing contracts, radiology utilization, supply reliability, and clinical preference.
What patents protect gadoteridol and ProHance?
The core patent estate for gadoteridol is expired. The foundational U.S. patent covering gadolinium chelates associated with ProHance was U.S. Patent No. 5,238,658, which expired after the end of its statutory term, subject to applicable patent-term adjustments and any relevant patent-term extension. The original composition and use protection therefore does not provide current market exclusivity.
Is ProHance protected by active Orange Book patents?
No currently meaningful composition-of-matter exclusivity remains for gadoteridol. Public FDA Orange Book records should be reviewed for any product-specific listing associated with a particular presentation, but ProHance is generally treated as an off-patent MRI contrast product rather than a product with an active core patent barrier [2].
| IP category |
Current commercial effect |
| Core gadoteridol composition |
Expired |
| Original MRI use claims |
Expired or commercially ineffective |
| Product formulation claims |
Limited potential relevance |
| Delivery-system claims |
Generally immaterial to standard ProHance injection |
| Manufacturing know-how |
Potential operational barrier, not market exclusivity |
| Orange Book exclusivity |
No material remaining core exclusivity |
Manufacturing know-how can still affect cost, impurity control, sterilization, quality systems, and supply reliability. It does not normally prevent an approved generic manufacturer from entering after satisfying FDA requirements.
When does gadoteridol lose exclusivity?
Gadoteridol lost meaningful U.S. exclusivity years ago. Its original FDA approval date does not create a current exclusivity period, and no small-molecule regulatory exclusivity is available today.
The relevant commercial timeline is:
| Period |
Event |
Market effect |
| 1992 |
FDA approval of ProHance |
Bracco receives originator market position |
| 1990s-2000s |
Expansion of MRI contrast use |
Volume growth |
| 2010s |
Increased attention to gadolinium retention and renal safety |
Shift toward macrocyclic agents |
| 2010s-present |
Mature product and generic competition |
Price and contracting pressure |
| Current market |
ProHance competes with multiple macrocyclic GBCAs |
No core patent-based barrier |
Paragraph IV litigation risk is therefore associated with formulation, process, labeling, or presentation claims rather than with the foundational gadoteridol molecule. A generic entrant would more likely rely on an abbreviated new drug application and a patent certification strategy than confront a durable composition patent.
How strong is the gadoteridol patent estate?
The patent estate is weak from an exclusivity perspective and moderate from an operational perspective.
Exclusivity strength
The core molecule is old, the FDA approval is more than three decades old, and the principal commercial presentation is a conventional sterile injectable. These factors reduce the likelihood that a new patent could block broad generic competition.
Manufacturing strength
Sterile contrast-agent manufacturing has technical requirements involving:
- Control of gadolinium complexation
- Removal of free gadolinium and process impurities
- Sterility assurance
- Endotoxin control
- Stability in the final container
- Consistency across production lots
These requirements can delay or complicate entry, but they are regulatory and manufacturing hurdles rather than durable patent protection.
Litigation strength
Gadoteridol has a lower litigation profile than newer specialty pharmaceuticals. The most likely disputes would involve:
- Orange Book patent listing validity
- Paragraph IV certifications
- Labeling carve-outs
- Injectable formulation claims
- Manufacturing-process patents
- Contracting or supply disputes
No active, high-value patent dispute is central to the current commercial position of ProHance based on the product’s mature lifecycle.
What is the competitive landscape for gadoteridol?
Gadoteridol competes in the macrocyclic GBCA segment, which has gained share relative to older linear agents because macrocyclic chelates generally have greater thermodynamic and kinetic stability.
| Product |
Active ingredient |
Commercial position |
| ProHance |
Gadoteridol |
Established macrocyclic, nonionic agent |
| Gadavist |
Gadobutrol |
Strong branded and hospital-contract competitor |
| Dotarem |
Gadoterate meglumine |
Established macrocyclic ionic competitor |
| MultiHance |
Gadobenate dimeglumine |
Linear agent with hepatobiliary properties |
| Eovist |
Gadoxetate disodium |
Liver-specific imaging positioning |
| Generic GBCAs |
Various |
Price pressure where available |
Gadavist and Dotarem are the closest clinical and commercial comparators. Gadobutrol has strong dose-concentration and broad MRI positioning. Gadoterate benefits from macrocyclic stability and broad global use. ProHance retains a long-established safety and workflow profile but lacks the growth characteristics of a recently launched product.
How do macrocyclic competitors compare with gadoteridol?
| Factor |
Gadoteridol |
Gadobutrol |
Gadoterate meglumine |
| Chelate structure |
Macrocyclic |
Macrocyclic |
Macrocyclic |
| Ionicity |
Nonionic |
Nonionic |
Ionic |
| Primary positioning |
CNS and general MRI |
General MRI, including CNS |
General MRI |
| Commercial maturity |
Mature |
Mature but commercially strong |
Mature |
| Patent leverage |
Minimal |
Primarily lifecycle and product-specific rights |
Primarily lifecycle and product-specific rights |
| Generic exposure |
High |
Increasing |
Increasing |
| Main differentiation |
Established use and macrocyclic profile |
Concentration, brand, contracting |
Clinical familiarity and global availability |
Clinical differentiation among macrocyclic agents is limited in many routine MRI applications. Purchasing decisions therefore rely heavily on net price, supply, hospital formulary agreements, injector compatibility, and vendor consolidation.
What is the financial trajectory of gadoteridol?
Standalone ProHance revenue is not publicly reported by Bracco. Bracco is privately held and does not provide the same product-level financial detail as a public pharmaceutical company. As a result, revenue, operating margin, and annual growth cannot be stated reliably from public company filings.
The product’s likely financial trajectory has four phases:
Launch and expansion
ProHance benefited from increasing MRI utilization and the expansion of contrast-enhanced imaging. Earlier commercial growth was driven by procedure volume rather than by repeat pharmaceutical treatment.
Maturity
The product entered a mature phase as hospitals adopted multiple competing GBCAs and procurement organizations increased purchasing leverage. Revenue growth became tied to MRI procedure growth and account retention.
Safety-driven mix shift
Concern over gadolinium retention and NSF improved the relative position of macrocyclic agents compared with some linear products. This supported continued demand for ProHance but did not restore originator-level pricing power.
Mature competitive erosion
The current trajectory is likely characterized by stable or declining net sales, depending on geographic market and generic availability. Volume may rise with MRI utilization while revenue declines because of discounts, tendering, and generic substitution.
| Financial driver |
Directional effect on ProHance |
| MRI procedure growth |
Positive |
| Preference for macrocyclic agents |
Positive |
| Generic entry |
Negative |
| Hospital group purchasing |
Negative |
| Branded premium pricing |
Negative |
| Supply reliability |
Positive if competitors experience shortages |
| Gadolinium safety concerns |
Mixed, with macrocyclic agents relatively advantaged |
| New indication expansion |
Limited |
What revenue exposure does gadoteridol create for Bracco?
ProHance is strategically relevant but unlikely to be one of Bracco’s highest-growth assets. Bracco’s broader portfolio includes diagnostic imaging agents, oncology imaging products, and imaging equipment-related businesses. The company does not disclose ProHance revenue separately in public financial materials.
Revenue exposure is concentrated in:
- Hospital and outpatient MRI volumes
- Radiology department formularies
- Group purchasing organization contracts
- International tender markets
- Generic availability by country
- Product supply continuity
The product is less exposed to payer reimbursement changes than therapeutic drugs because contrast agents are usually purchased as part of imaging procedures. It is more exposed to hospital procurement decisions and per-dose contract pricing.
What generic entry risks exist for gadoteridol?
Generic entry risk is high in principle because the core molecule is off-patent. The actual timing and commercial impact depend on FDA approvals, manufacturing readiness, supply economics, and contracting.
Generic launch scenarios
| Scenario |
Likely effect |
| No approved generic |
ProHance retains brand presence but faces contract discounts |
| One generic entrant |
Moderate price erosion and selective substitution |
| Multiple generic entrants |
Significant net-price decline and formulary conversion |
| Generic shortage or quality failure |
Temporary restoration of branded demand |
| Hospital multisource tender |
Rapid conversion toward lowest-cost supplier |
An ANDA applicant would need to demonstrate pharmaceutical equivalence and bioequivalence or satisfy applicable requirements for an injectable product. The applicant could use a Paragraph IV certification if it challenged any listed patent, or a Section VIII statement if it omitted a protected method of use. With the core patent estate expired, the legal pathway is more straightforward than for a recently approved drug.
Are biosimilars a risk to gadoteridol?
No. Gadoteridol is a chemically synthesized small molecule and an imaging contrast agent. It is not a biologic and does not face biosimilar substitution. The relevant competitive threats are generic gadoteridol products and competing branded GBCAs.
What formulation patents protect gadoteridol?
The commercial product is a conventional aqueous intravenous formulation. Potential formulation protection could cover concentration, pH, excipient selection, container configuration, stability, or manufacturing controls. Such claims are narrower than a composition patent and generally have limited blocking power if an alternative formulation can meet the same FDA specifications.
No formulation feature is publicly established as a durable, high-value barrier to generic gadoteridol. The principal barrier is compliance with sterile injectable manufacturing and FDA approval standards.
What litigation and settlement risks affect ProHance?
The litigation risk is low compared with products that retain active composition patents or have major Orange Book portfolios. Potential legal events include:
- Paragraph IV patent challenges by generic manufacturers
- Patent-listing disputes
- Declaratory judgment actions
- Labeling disputes involving MRI indications
- Manufacturing-process litigation
- Product-liability claims involving gadolinium retention or hypersensitivity
No major publicly documented settlement agreement is central to the present ProHance market outlook. A future generic settlement would have greater commercial importance if it established an early launch date or restricted supply terms, but the age of the product reduces the likelihood of a high-value exclusivity settlement.
How does gadoteridol compare with newer MRI contrast agents?
Gadoteridol has strong lifecycle stability but limited innovation upside. Newer agents can gain share through disease-specific imaging, higher concentration, reduced injection volume, hepatobiliary uptake, or improved workflow economics.
ProHance is most defensible where clinicians value:
- Macrocyclic chelate chemistry
- Long clinical experience
- Established CNS imaging use
- Existing hospital contracts
- Integration with radiology protocols
Its weaker points are the absence of a unique high-growth indication and limited ability to command a substantial premium over other macrocyclic agents.
What is the geographic coverage of gadoteridol?
ProHance has been marketed in the United States and international markets under Bracco’s diagnostic imaging business. The competitive position varies by country because generic approval, reimbursement, tendering, and product registration differ across jurisdictions.
The United States is likely to remain a high-value market because of MRI utilization and hospital purchasing scale. European and other public-tender markets can impose greater price pressure. In emerging markets, growth in MRI installations can support unit demand, but local manufacturing, registration, and tender competition can reduce net pricing.
Key Takeaways
- Gadoteridol, marketed as ProHance, is a mature macrocyclic GBCA approved by the FDA in 1992.
- The core patent estate has expired, leaving no meaningful molecule-level exclusivity.
- ProHance has no biosimilar risk because gadoteridol is a small molecule, not a biologic.
- Generic risk is structurally high, although actual erosion depends on ANDA approvals, supply, and hospital contracts.
- Gadobutrol and gadoterate meglumine are the closest commercial competitors.
- Macrocyclic positioning supports demand amid gadolinium-retention concerns, but it does not eliminate price pressure.
- Bracco does not disclose standalone ProHance revenue, preventing a reliable product-level sales forecast.
- The most likely financial trajectory is mature or declining net revenue, offset in part by MRI procedure growth and continued use of macrocyclic agents.
- Sterile injectable manufacturing is a practical barrier, but it is not equivalent to patent exclusivity.
- No major active patent litigation or settlement is central to the current ProHance outlook.
FAQs About Gadoteridol Market and Exclusivity
Is gadoteridol still commercially viable?
Yes. ProHance remains commercially viable because MRI volumes are substantial and macrocyclic agents retain clinical demand. Its economics are mature and contract-driven rather than growth-oriented.
Does gadoteridol have a new chemical entity exclusivity period remaining?
No. Any original new chemical entity exclusivity expired decades ago following the 1992 FDA approval.
Can a generic company launch gadoteridol without challenging a patent?
Yes, if no unexpired patent blocks the relevant product or use. An applicant could file an ANDA using a certification strategy consistent with the patents listed for the reference product.
Is ProHance safer than linear gadolinium contrast agents?
Macrocyclic agents such as gadoteridol generally have greater chelate stability than many linear agents. The FDA still warns that gadolinium retention can occur and requires risk-based use, particularly in patients with renal impairment [3].
What is the main investment risk for gadoteridol?
The main risk is net-price erosion from generic entry and hospital purchasing pressure. The main support is sustained MRI utilization and continued preference for macrocyclic GBCAs.
References
-
U.S. Food and Drug Administration. (2023). ProHance (gadoteridol injection) prescribing information. Bracco Diagnostics Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2018). Gadolinium-based contrast agents: Drug safety communication. FDA.
-
American College of Radiology. (2024). ACR manual on contrast media. American College of Radiology.
-
Bracco Diagnostics Inc. (2024). ProHance product information. Bracco.
